Product Information
IMVEXXY 4 MCG STARTER PACK is a brand product labeled by Mayne Pharma, priced at $27.1090 per EA under NDC 68308074718. Its NADAC has been published 93 times since Nov 13, 2024.
FDA first approved this application on May 29, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the estradiol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
4 ug/1
Manufacturer
Mayne PharmaNDC
68308074718
Classification
Brand
Dosage Form
INSERT
Route
VAGINAL
Effective Date
6/1/2026
Active Ingredients
ESTRADIOLApproval Type
New Drug (NDA)
FDA Application
NDA208564FDA Approved
5/29/2018
TE Code
AB
On Market Since
5/3/2024
Pharmacological Classes
Price Statistics
The NADAC for IMVEXXY 4 MCG STARTER PACK has been published 93 times since Nov 13, 2024, and over the history we have for it it has risen 4.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $27.1090 per EA |
|---|---|
| All-time high | $27.1090 (Aug 19, 2026) |
| All-time low | $25.8181 (May 20, 2026) |
| 52-week high | $27.1090 |
| 52-week low | $25.8181 |
| Median price | $25.8525 |
| Average price | $26.0215 |
| Largest weekly change | +5.0% (Jun 3, 2026) |
| Weeks tracked | 93 |
| Tracking since | Nov 13, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of IMVEXXY 4 MCG STARTER PACK?
The current National Average Drug Acquisition Cost (NADAC) for IMVEXXY 4 MCG STARTER PACK, manufactured by Mayne Pharma, is $27.1090 per EA (NDC 68308074718), effective Aug 19, 2026.
How has the price of IMVEXXY 4 MCG STARTER PACK changed over time?
Over the history we have for it, the NADAC for IMVEXXY 4 MCG STARTER PACK has risen 4.6%. It has been tracked across 93 weekly CMS publications since Nov 13, 2024.
What are the highest and lowest recorded NADAC prices for IMVEXXY 4 MCG STARTER PACK?
Since Nov 13, 2024, the NADAC for IMVEXXY 4 MCG STARTER PACK has ranged from a low of $25.8181 (May 20, 2026) to a high of $27.1090 (Aug 19, 2026), with a median of $25.8525 per EA.
Are there cheaper alternatives to IMVEXXY 4 MCG STARTER PACK?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMVEXXY 4 MCG MAINTENANCE PACK, is $27.0962 per EA — about 0% below IMVEXXY 4 MCG STARTER PACK.
Who manufactures IMVEXXY 4 MCG STARTER PACK?
IMVEXXY 4 MCG STARTER PACK (NDC 68308074718) is labeled by Mayne Pharma, and CMS classifies it as a brand product.